Literature DB >> 32475708

An analysis of unplanned readmissions after head and neck microvascular reconstructive surgery.

A Weyh1, R Nocella2, M Abdelmalik3, R Pucci4, A Quimby5, A Bunnell6, R Fernandes7.   

Abstract

The 30-day readmission rate is a highly scrutinized metric of quality surgical care, because readmission is costly and perceived to be avoidable with planning and patient education. Head and neck surgery patients generally have multiple risk factors for readmission, as readmitted patients are generally older, with more co-morbidities, lower socio-economic status, and a history of multiple emergency department visits and readmissions. A retrospective cohort study was implemented to determine the incidence and etiology of 30-day readmission after microvascular head and neck reconstructive surgery, focusing on social risk factors. Data were analyzed by χ2 test, analysis of variance, t-test, and logistic regression, with statistical significance set at P<0.05. Of 209 patients included in this study, 35 (16.7%) had a 30-day readmission. Increased needs at discharge were associated with increased readmission, while other social risk factors were less significant for a readmission in this study.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  complications; healthcare system; microvascular surgery; quality metric; readmissions; rehospitalizations

Year:  2020        PMID: 32475708     DOI: 10.1016/j.ijom.2020.04.017

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  1 in total

1.  The Impact of Healthcare-Associated Infections in Patients Undergoing Oncological Microvascular Head and Neck Reconstruction: A Prospective Multicentre Study.

Authors:  Ana Ramos-Zayas; Francisco López-Medrano; Irene Urquiza-Fornovi; Ignacio Zubillaga; Ramón Gutiérrez; Gregorio Sánchez-Aniceto; Julio Acero; Fernando Almeida; Ana Galdona; María José Morán; Marta Pampin; José Luis Cebrián
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.